CRISPR Therapeutics (NASDAQ:CRSP) Raised to Sell at StockNews.com

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) to a sell rating in a research note released on Friday morning.

A number of other equities research analysts also recently weighed in on CRSP. Piper Sandler reiterated an overweight rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a report on Monday, June 17th. Barclays lowered their price objective on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an equal weight rating for the company in a research note on Tuesday, August 6th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They set a buy rating and a $90.00 target price on the stock. Royal Bank of Canada decreased their price target on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a sector perform rating for the company in a research note on Tuesday, August 6th. Finally, Needham & Company LLC cut their price objective on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a buy rating on the stock in a research report on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $75.63.

CRISPR Therapeutics Stock Down 2.0 %

CRSP opened at $47.85 on Friday. The stock has a market cap of $4.06 billion, a PE ratio of -17.59 and a beta of 1.70. CRISPR Therapeutics has a twelve month low of $37.55 and a twelve month high of $91.10. The company has a fifty day moving average of $55.49 and a 200-day moving average of $62.18.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. The company’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.98) EPS. Sell-side analysts anticipate that CRISPR Therapeutics will post -5.52 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. increased its stake in CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the last quarter. Global Trust Asset Management LLC grew its holdings in shares of CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC increased its position in shares of CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the last quarter. NBC Securities Inc. lifted its holdings in CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after acquiring an additional 438 shares during the period. Finally, GPS Wealth Strategies Group LLC boosted its position in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.